Biocon Chair Kiran Mazumdar-Shaw Unveils Five-Year Succession Roadmap, Names Niece as Future Chair

Kiran Mazumdar-Shaw, founder and chairperson of Biocon, has announced a phased leadership succession plan over the next five years, naming her niece Claire Mazumdar as her eventual successor for the role of chair.

Speaking about the transition, Mazumdar-Shaw said the process would happen gradually, with Claire expected to move step-by-step through leadership responsibilities, beginning from a director-level role and eventually progressing to vice-chair and chairperson. She emphasized that while she is not stepping away immediately, she wants to ensure continuity and long-term stewardship of the company.

Founded in 1978 in Bengaluru, Biocon has grown from a small startup operating out of a garage into one of the world’s leading biosimilars manufacturers. Today, the company has a significant global presence, particularly in the United States and Europe, with a portfolio of more than 30 biosimilars, including commercially launched products and several in development. The company has played a pioneering role in biosimilar insulin and other complex biologic therapies used in the treatment of cancer, diabetes, rheumatoid arthritis, and related conditions.

Mazumdar-Shaw highlighted the importance of preserving the family legacy at Biocon, where her family members have historically remained closely involved with the business. She currently holds nearly a 30% stake in the company.

Claire Mazumdar currently serves as the founding CEO of Bicara Therapeutics, an oncology-focused biotechnology company that was incubated with early backing from Kiran Mazumdar-Shaw and listed publicly in 2024. Prior to Bicara, Claire worked in business development and corporate strategy at Rheos Medicines and was associated with Third Rock Ventures, where she focused on company formation and innovation-led ventures.

She also holds a PhD in cancer biology from Stanford School of Medicine, bringing a strong scientific and strategic foundation to the role.

The planned transition reflects a broader trend among founder-led companies toward structured succession planning and long-term leadership continuity. For Biocon, the move signals an effort to balance continuity with future-focused leadership as the company continues to expand its global biosimilars and biotechnology footprint.